Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

Executive Summary

By granting an approval four months ahead of schedule of Roche AG's and Genentech Inc.'s anti-PD-LI cancer immunotherapy Tecentriq (atezolizumab), the FDA may have helped the companies secure a better lead in the bladder cancer marketplace than the firms otherwise would have held. But already established immunotherapies, Merck & Co. Inc.'s Keytruda (pembrolizumab) and Bristol-Myer Squibb Co.'s Opdivo (nivolumab), are in hot pursuit.

Advertisement

Related Content

Quick Commercial Standouts Lacking Among 2016 US Launches
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
Keytruda, Opdivo Set To Challenge Tecentriq In Bladder Cancer
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Is It The End For OncoGenex? Custirsen Fails In Second Phase III Prostate Cancer Trial
German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space
FDA Pazdur's Opdivo Love Affair And Other Adventures
Merck's Keytruda: A Remarkable Science-To-Success Story
Merck melanoma drug Keytruda OK'd; 1st US PD-1

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel